Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Endometrial Neoplasms 2Polycystic Ovary Syndrome 1Ovarian Neoplasms 1Multiple Endocrine Neoplasia Type 1 1Leukemia, Lymphocytic, Chronic, B-Cell 1Endometrial Hyperplasia 1

Interventions

Rituximab 313Cyclophosphamide 286fludarabine phosphate 213fludarabine 140ibrutinib 121Peripheral Blood Stem Cell Transplantation 116venetoclax 108Mycophenolic Acid 102obinutuzumab 88Lenalidomide 88Bendamustine Hydrochloride 87Whole-Body Irradiation 85Filgrastim 84Tacrolimus 78Cyclosporine 78Busulfan 70Melphalan 65Radiotherapy 63Antilymphocyte Serum 61Alemtuzumab 58Etoposide 56acalabrutinib 54Methotrexate 49ofatumumab 46idelalisib 38Cytarabine 33Chlorambucil 33zanubrutinib 31sargramostim 30Specimen Handling 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Lymphocytic, Chronic, B-Cell × Levonorgestrel × Clear all
NCT03301207 2019-12-05

A Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Participants With B Cell Malignancy

Janssen Research & Development, LLC

Phase 1 Completed
25 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡